Skip to content

Blog

Author: Scientific Office

<a href="https://www.bioagilytix.com/blog/category/industry-update/">Industry Update</a>

The Impact of Brexit on European Biotech and Biopharma

  • October 23, 2020

At the commencement of her national campaign in July 2016, the former UK Prime Minister Theresa May stated, “It is hard to think of an…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioanalytical-platforms/">Bioanalytical Platforms</a>

What to Expect at AAPS 2020 PharmSci 360

  • October 14, 2020

It’s that time of the year again. October 26th marks the beginning of the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 event. This yearly…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/cell-based-assays/">Cell-Based Assays</a>

Utilizing Bradford Assay for Protein Concentration Calculation

  • October 9, 2020

If your goal is to attain swift and simple protein quantification, the Bradford assay is the way to go. Let’s find out more about what…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/cell-based-assays/">Cell-Based Assays</a>

A Beginner’s Guide to Luciferase Assays

  • October 9, 2020

Luciferase is an enzyme used by a variety of organisms for bioluminescence. One of the most common examples of bioluminescence exists in the biology of…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/pharmacokinetics/">Pharmacokinetics</a>

The Difference Between Pharmacokinetics and Pharmacodynamics

  • October 5, 2020

In the United States, the safety and efficacy of prescription and over-the-counter drugs are a top priority for our government, medical professionals, and pharmaceutical companies.…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

BioAgilytix’s Boston Team Q&A: Meet Benjamin Lamothe, Clinical Research Scientist

  • August 26, 2020

The best science demands the best people—and at BioAgilytix’s Boston lab, there’s no shortage of skilled and dedicated scientists. Get to know one of our…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

CLIA, COLA & CAP: What’s the Difference?

  • August 19, 2020

BioAgilytix’s CLIA Laboratory Director, Natalie Smith, outlines the differences between CLIA, CAP & COLA regulations & accreditations, and what they mean for laboratory testing quality.

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

Making the Move: A Look into the Career Transition from Pharma/Biotech to CRO

  • August 12, 2020

In our recruitment process we are often asked by those coming from pharma & biotech careers, “what’s a day in the life like at a…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/gene-therapy/">Gene Therapy</a>

Impact of Pre-Existing Immunogenicity Against AAV on Gene Therapy Trials

  • July 23, 2020

The concept of using pre-existing immunogenicity as an exclusion criteria for gene therapy clinical trials is changing. BioAgilytix’s Chief Scientific Officer, Dr. Jim McNally, explores…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

Behind the Science Perspectives with Dr. Jim McNally, BioAgilytix’s Chief Scientific Officer

  • June 25, 2020

We recently sat down with Dr. Jim McNally for a Q&A to hear his "Behind the Science" perspectives on the industry and where he thinks…

Find Out More